MNKD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
MannKind Corp (MNKD) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is facing significant uncertainty due to potential competition from United Therapeutics' new soft mist inhaler, which could impact MannKind's royalty streams. Additionally, the company's financial performance has been weak, with declining net income and EPS. While the stock is oversold technically, there are no strong proprietary trading signals or positive catalysts to justify immediate investment. A hold strategy is recommended until more clarity on competitive risks and financial recovery is evident.
The stock is technically oversold with an RSI of 6.222, indicating potential for a short-term bounce. However, the MACD histogram is negative and expanding downward, suggesting bearish momentum. The stock is trading below key support levels, with S1 at 3.525 and S2 at 2.857. Converging moving averages further indicate indecision in price direction.
MannKind reported a 46% year-over-year revenue increase for Q4 2025, showing strong growth in sales for Furoscix and Afrezza. Additionally, the company finalized the acquisition of sCPharmaceuticals, which could enhance future growth potential.
United Therapeutics' development of a soft mist inhaler poses a significant competitive risk to MannKind's Tyvaso DPI royalties. The company's Q4 2025 financials showed a substantial decline in net income and EPS, missing analyst expectations. Hedge funds are also selling heavily, with a 337.78% increase in selling activity over the last quarter.
MannKind's Q4 2025 financials showed revenue of $112 million, a 46% year-over-year increase. However, net income dropped significantly to $1.5 million, missing expectations. EPS also fell to $0.01, reflecting weak profitability despite revenue growth.
Analysts remain cautiously optimistic with Buy and Outperform ratings, but they acknowledge significant risks from United Therapeutics' competitive product. Price targets range from $7.50 to $11, indicating potential upside if risks are mitigated.
